$3.10 Million in Sales Expected for Unum Therapeutics Inc (NASDAQ:UMRX) This Quarter

Wall Street brokerages expect that Unum Therapeutics Inc (NASDAQ:UMRX) will report $3.10 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Unum Therapeutics’ earnings, with the highest sales estimate coming in at $4.41 million and the lowest estimate coming in at $1.80 million. Unum Therapeutics reported sales of $1.67 million in the same quarter last year, which indicates a positive year-over-year growth rate of 85.6%. The firm is expected to announce its next quarterly earnings report on Monday, August 12th.

On average, analysts expect that Unum Therapeutics will report full-year sales of $13.82 million for the current year, with estimates ranging from $8.30 million to $17.60 million. For the next fiscal year, analysts anticipate that the company will post sales of $16.91 million, with estimates ranging from $9.00 million to $25.33 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.08). Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.15 million.

UMRX has been the topic of several research analyst reports. Cowen initiated coverage on Unum Therapeutics in a research report on Tuesday, February 26th. They issued a “market perform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Unum Therapeutics in a research report on Tuesday, May 14th. Zacks Investment Research downgraded Unum Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Finally, SunTrust Banks lowered their price objective on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a research report on Friday, March 29th. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $14.60.

Shares of Unum Therapeutics stock opened at $2.32 on Wednesday. The firm has a 50-day simple moving average of $3.06. Unum Therapeutics has a 52 week low of $2.28 and a 52 week high of $17.66. The stock has a market capitalization of $71.98 million, a P/E ratio of -1.67 and a beta of 1.75. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.11.

Large investors have recently bought and sold shares of the stock. Wasatch Advisors Inc. raised its position in Unum Therapeutics by 64.5% in the first quarter. Wasatch Advisors Inc. now owns 254,449 shares of the company’s stock valued at $1,117,000 after purchasing an additional 99,814 shares during the period. Rhumbline Advisers purchased a new stake in Unum Therapeutics in the first quarter valued at approximately $85,000. Deutsche Bank AG raised its position in Unum Therapeutics by 72.4% in the fourth quarter. Deutsche Bank AG now owns 63,657 shares of the company’s stock valued at $279,000 after purchasing an additional 26,742 shares during the period. D. E. Shaw & Co. Inc. raised its position in Unum Therapeutics by 7.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock valued at $242,000 after purchasing an additional 3,846 shares during the period. Finally, Bank of America Corp DE raised its position in Unum Therapeutics by 11.6% in the fourth quarter. Bank of America Corp DE now owns 99,545 shares of the company’s stock valued at $438,000 after purchasing an additional 10,317 shares during the period. Institutional investors own 47.27% of the company’s stock.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Read More: Diversification Important in Investing

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.